GSK shares technical analysis: Overbought conditions highlight reversal setup

Traders Union
All News
Stocks
GSK drops 1.26% today to GBX1,845

Highlights

GSK plans to eliminate up to 1,217 jobs in Belgium to reduce costs and improve operational efficiency.
Management expects the restructuring to support future profitability, but short-term uncertainty may affect local sentiment.
Shares of GSK closed at GBX1,845 after falling 1.26%, with mixed technical signals and an expected trading range of GBX1,783 to GBX1,910 for the coming sessions.

Job cuts drive cost focus but fuel local uncertainty and negative tone

GSK is planning to eliminate up to 1,217 jobs in Belgium as part of a corporate restructuring effort, according to Latestly. This move signals management's intent to address cost structures and improve operational efficiency, which could support future profitability. However, workforce reductions of this scale often introduce short-term uncertainty and may weigh on local sentiment, aligning with the current price direction.

Buy signals dominate amid overbought risks and mixed momentum cues

On the hourly chart, GSK is trading above the MA-20 at GBX1,806 and the MA-50 at GBX1,782, while remaining below the long-term MA-200 at GBX1,951. The Ichimoku Kijun sits at GBX1,808 and provides immediate support. Momentum indicators are mixed: MACD, ADX, and CCI each register Buy signals, while RSI is elevated at 63.9, showing a buy-side tilt but nearing overbought conditions. Stochastic RSI is neutral, CCI signals Buy, and Bull/Bear Power suggests overbought intraday conditions. The Awesome Oscillator remains neutral, offering little confirmation for further upside.

Consolidation likely as breakout hinges on resistance and support levels

In the near term, the expected price range for GSK is GBX1,783 to GBX1,910. Price is anticipated to consolidate within this corridor, with a 70% likelihood of sideways or upward movement and 30% probability of a downward move. A close above resistance may prompt a breakout toward the upper end of the range, while a slip below immediate support could trigger a test of the lower boundary.

Viktoras Karapetjanc, expert at Traders Union, sees GSK's restructuring effort as a positive step for cost management and future earnings. He believes the job cuts, though difficult, signal management’s resolve to optimize operations. Technical momentum remains supportive above key short-term levels, even with mixed signals. In his view, the balance of risks favors consolidation or gradual upside. "I remain constructive on GSK’s medium-term prospects, as operational discipline and improving sentiment could unlock further value if technical supports hold."

Earlier, analysts noted that while insider share purchases provided support to GSK, persistent technical resistance maintained a cautious outlook. The current technical alignment underscores a watchful stance, with traders advised to monitor for a potential breakout or breakdown from the GBX1,783 to GBX1,910 trading corridor as new restructuring measures unfold.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.